Most patients with refractory lymphoma manifest as double-hit lymphoma (MYC-BCL2 rearrangement) (DHL) or double-expression lymphoma (MYC-BCL2 overexpression) (DEL), with more invasive manifestations clinically. This evidence concerns the gene MYC and lymphoma.